跳至主要内容
临床试验/NCT03323554
NCT03323554进行中(未招募)不适用

Prospective Interventional Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence. an Open, Randomised, Multicentre Study Versus Artificial Sphincter.

Quanta Medical2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2018年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
20
试验地点
2
主要终点
comparison of succes rate

研究概览

简要总结

Few surgical methods to treat male stress urinary incontinence have been assessed in comparative, randomised interventional studies.

Ustrap is a new adjustable-pressure 4-arm device. The artificial sphincter is currently considered the gold standard device in this field.

The aim of this randomised prospective international study is to assess the efficacy and safety of the Ustrap® device comparatively with an artificial sphincter (AMS800) in the treatment of stress urinary incontinence following prostate removal in cancer patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Disease-related criteria:
  • persistent urinary incontinence >= 12 months following radical prostatectomy for prostate adenocarcinoma
  • presenting an indication for surgical insertion of a medical device
  • 24h PAD test > 100 g per day
  • controlled prostate adenocarcinoma, with PSA ≤ 1 ng/ml
  • Population-related criteria:
  • male subjects aged 18 years and over
  • having provided free, informed written consent to take part in the study
  • patients independent and able to use the collar without difficulty and able to manage an artificial sphincter
  • Patient able to understand and sign the consent form and to complete questionnaires
  • Patient without mental impairment
  • Patients belonging to or covered by Social Security.

排除标准

  • Disease-related criteria:
  • Documented neurological bladder or history of neurological disease liable to interfere with urinary symptoms.
  • Presence of urethral anastomotic stenosis preventing passage of the fiberscope at the initial endoscopy
  • Severe symptomatic hyperactive or hypoactive bladder not controlled by drug therapy
  • Severe constitutional haemorrhagic disease or haemophilia
  • Patients presenting urinary infection not controlled
  • Patients presenting severe renal failure and obstructive pathologies of the upper urinary tract with severe renal failure.
  • Patients presenting deep immune deficiency
  • Patient presenting recto-urethral fistula
  • Patient with tumor of bladder
  • Patient having bladder stones with failure of bladder stone treatment
  • Criteria related to incontinence treatment:
  • Allergy to any of the components of the medical devices
  • History of surgery to insert a medical device for treatment of incontinence (e.g. artificial sphincter, suburethral strap, continence balloons, etc.)
  • History of periurethral injection of filling agents
  • Inability to use either of the study devices
  • Drug treatment: duloxetine or any treatment likely to modify continence results
  • Not receiving and not likely to receive radiotherapy at any time throughout the 12-month follow-up period Population-related criteria
  • Foreseeable unavailability during the study . Patient deprived of liberty by administrative or judicial decision or under legal guardianship
  • Participation in another clinical trial in the 3 months preceding the initial visit

结局指标

主要结局

comparison of succes rate

时间窗: 12 months

Succes being defined as the absence of use of protective pads, or in the case of use of safety protection comprising a test PAD over 24h, wet weight indicating collection of ≤ 10 g liquid, and the absence of corrective surgery.

次要结局

未报告次要终点

研究者

发起方
Quanta Medical
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验